Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
about
Novel therapeutic agents in the treatment of metastatic colorectal cancerQuality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available dataMeta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition.Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerBiomarker in Colorectal Cancer.First-line chemotherapy for mCRC—a review and evidence-based algorithm.Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.Current and advancing treatments for metastatic colorectal cancer.Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives.Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer.Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.Who will benefit more from maintenance therapy of metastatic colorectal cancer?FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
P2860
Q26769932-DAD29926-68B3-4310-92D7-2CDCF5B0164BQ30313818-2334806F-E5D6-4242-B541-058EF256BE4BQ30317446-6E8C3455-0E6E-4705-87F9-4FCA6EF8C3D7Q30855372-7B57373A-1780-4415-9C84-BDAB85DADD4EQ30862367-DE8ED941-F288-41CE-AC5D-7B01CF59F820Q33443519-0AE91E8D-00AC-4450-9F1F-7FAE499246AFQ33576199-302D5020-E84C-467B-94E0-9842B58720B3Q33650400-898ED4D5-AD44-4A77-9804-3347B4FD6A21Q36143977-2E2C1537-63EF-4B72-9E48-3CD938CCBC6CQ36706109-B2394E27-FF99-443C-9858-FB03A8324DC9Q37114675-A1C96158-E8BC-4630-93EC-3D8CE8ECAE3CQ38555200-3C42C737-7D80-48F6-94E4-9AF3CE0F895AQ38617495-2C7F6C12-D4C4-43B6-A758-1F84FF6FEAD9Q38628257-F1392CD1-0F3B-40D1-8DD7-B4609680DDEFQ40040773-3EDCD8FE-2AAD-4086-A478-567548B2D1A6Q41201235-58DBD174-7356-4F2F-AF59-7A3FD56147EFQ41918821-1ADF63D4-35D8-43E7-8336-DE817FACCE93Q47719824-F46A86BD-C693-4B41-8EB5-996B2671A2F8Q48507263-D73EA45A-FC89-4A1C-A8F2-610DDBCFF83DQ49951874-D3275189-527E-4A08-8F92-54BFB706B616Q50088434-A4A3D617-3F89-4BC8-B7CF-CA95BBA6D10DQ50350183-F7323665-31D2-403D-8C23-594BEFA3DF66Q50872828-61047741-23B5-41A3-B95D-81B8BE694F94Q52649576-A66CDA09-3393-4F62-9910-446E68FE4B3FQ53179257-398B7BBB-0EC7-4862-AA5D-F37D67721665Q55032398-D9A9AF76-683C-4DF9-9535-C4485CBBE5E6Q58729601-C02889DA-4546-47F7-A6A2-229C04766D2B
P2860
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Bevacizumab continuation versu ...... nferiority trial (SAKK 41/06).
@en
Bevacizumab continuation versu ...... hase III non-inferiority trial
@nl
type
label
Bevacizumab continuation versu ...... nferiority trial (SAKK 41/06).
@en
Bevacizumab continuation versu ...... hase III non-inferiority trial
@nl
prefLabel
Bevacizumab continuation versu ...... nferiority trial (SAKK 41/06).
@en
Bevacizumab continuation versu ...... hase III non-inferiority trial
@nl
P2093
P921
P356
P1433
P1476
Bevacizumab continuation versu ...... nferiority trial (SAKK 41/06).
@en
P2093
D Baertschi
D C Betticher
D Dietrich
D Koeberle
P304
P356
10.1093/ANNONC/MDV011
P577
2015-01-20T00:00:00Z